[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lite Strategy Inc (LITS)

Lite Strategy Inc (LITS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,984
  • Shares Outstanding, K 34,025
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,950 K
  • EBIT $ -58 M
  • EBITDA $ -58 M
  • 60-Month Beta 0.21
  • Price/Sales N/A
  • Price/Cash Flow 0.15
  • Price/Book 0.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.60
  • Most Recent Earnings $-0.66 on 05/13/26
  • Next Earnings Date 09/25/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 232.66% (+34.32%)
  • Historical Volatility 47.96%
  • IV Percentile 59%
  • IV Rank 15.63%
  • IV High 870.12% on 07/10/26
  • IV Low 114.60% on 10/28/25
  • Expected Move (DTE 1) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 73
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 11,821
  • Open Int (30-Day) 11,720
  • Expected Range 0.9434 to 0.9434

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8503 +10.95%
on 08/10/26
1.0801 -12.66%
on 07/21/26
-0.0866 (-8.41%)
since 07/20/26
3-Month
0.6888 +36.96%
on 06/11/26
1.1350 -16.88%
on 05/21/26
-0.1766 (-15.77%)
since 05/20/26
52-Week
0.6888 +36.96%
on 06/11/26
5.5000 -82.85%
on 08/27/25
-3.6466 (-79.45%)
since 08/20/25

Most Recent Stories

More News
Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share

SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury...

LITS : 0.9434 (+0.36%)
Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

SAN DIEGO, June 19, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) ("Lite Strategy" or the "Company"), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve...

LITS : 0.9434 (+0.36%)
Lite Strategy Leads Strategic Investment in LitVM

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury...

LITS : 0.9434 (+0.36%)
Lite Strategy Reports Fiscal 2026 Third Quarter Results

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury...

LITS : 0.9434 (+0.36%)
Lite Strategy Reports Fiscal 2026 Second Quarter Results

SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury...

LITS : 0.9434 (+0.36%)
Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

Lite Strategy, Inc. (NASDAQ:LITS) (“Lite Strategy” or “LITS”) today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate

LITS : 0.9434 (+0.36%)
Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ: LITS) (“Lite Strategy” or “LITS”) today announced its Board of Directors has authorized a program to repurchase shares...

LITS : 0.9434 (+0.36%)
Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026

SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ: LITS) (“Lite Strategy” or “LITS”), the first U.S.-listed public company to adopt Litecoin as its primary reserve asset,...

LITS : 0.9434 (+0.36%)
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’

Lite Strategy Rebrand Aligns with Company’s LTC Digital Asset Treasury Strategy Advised by GSR Ventures

MEIP : 3.07 (+10.43%)
LITS : 0.9434 (+0.36%)
Canadian Investment Regulatory Organization Trading Halt - LITS

VANCOUVER, BC , Sept. 5, 2025 /CNW/ - The following issues have been halted by CIRO:

LITS : 0.9434 (+0.36%)

Business Summary

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards,...

See More

Key Turning Points

3rd Resistance Point 1.0542
2nd Resistance Point 1.0264
1st Resistance Point 0.9849
Last Price 0.9434
1st Support Level 0.9156
2nd Support Level 0.8878
3rd Support Level 0.8463

See More

52-Week High 5.5000
Fibonacci 61.8% 3.6621
Fibonacci 50% 3.0944
Fibonacci 38.2% 2.5267
Last Price 0.9434
52-Week Low 0.6888

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.